Ritonavir Mylan

  • Email
  • Help

Questions & Answers

On 14 September 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ritonavir Mylan, intended for the treatment of HIV infection. The applicant for this medicinal product is Mylan S.A.S.

Ritonavir Mylan will be available as 100 mg film-coated tablets. The active substance of Ritonavir Mylan is ritonavir, an antiviral for systemic use (ATC code: J05AE03). Ritonavir is an inhibitor of the viral protease enzyme, which is key for viral replication; however, in small doses it is used in combination with other protease inhibitors to slow down the rate at which the latter are metabolised by the liver.

Ritonavir Mylan is a generic of Norvir, which has been authorised in the EU since 26 August 1996. Studies have demonstrated the satisfactory quality of Ritonavir Mylan, and its bioequivalence to the reference product Norvir. 

The full indication is: "Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older)". It is proposed that Ritonavir Mylan be prescribed by physicians experienced in the management of HIV infection.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Name Language First published Last updated
CHMP summary of positive opinion for Ritonavir Mylan (English only) 2017-09-15  

Key facts

Product details for Ritonavir Mylan
NameRitonavir Mylan
INN or common nameritonavir
Therapeutic area HIV Infections
Active substance

ritonavir

Date opinion adopted14/09/2017
Company name

Mylan S.A.S.

StatusPositive
Application typeInitial authorisation

Related content